Non-Inteventional Fresh Tumor Tissue

tilize fresh tumor tissue to aid the development of future therapies for brain cancer.

Briefly, a cell immunotherapy consisting of a patient’s autologous glioblastoma tumor cells, called ‘IGV-001’, is being tested in clinical trials. In order to advance clinical and product development of IGV-001, Imvax is seeking access to patient material to test key product parameters in a laboratory setting.

The device used to collect the tissue, the Myriad multifunctional device enabling suction, resection, and collection of tumor tissue (see NICO Myriad Use Manual) is an FDA-approved device that is safe

Inclusion Criteria

• English speaking
• Any individual >18 years old
• Patients eligible for and undergoing craniotomy for diagnostic and therapeutic purposes. Please note: Patients undergoing craniotomy for presumed diagnosis of Grade IV GBM are eligible.

Exclusion Criteria

N/A

Study Requirements

The patient signs the informed consent form. Once the surgery is performed and the samples collected, the study period is concluded.